Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: Neurobiol Dis. 2006 Dec 29;26(1):201–211. doi: 10.1016/j.nbd.2006.12.011

Figure 3.

Figure 3

Effect of the D1/D5 dopamine receptor antagonist SCH23390 on amphetamine-mediated locomotor activity. Coloboma (A) and control mice (B) were treated with saline or 4 mg/kg amphetamine and challenged with SCH23390. Compared to vehicle treatment, amphetamine significantly increased locomotor activity in control mice (**p < 0.01, paired Student’s t test) but significantly reduced locomotor activity in coloboma mice (*p < 0.05, paired Student’s t test). Two-factor ANOVA with repeated measures revealed a significant effect of genotype (F1,12 = 25.22, p < 0.001) and dose of SCH23390 (F3,36 = 18.41, p < 0.0001) on amphetamine-mediated locomotor activity. 0.2 mg/kg SCH23390 resulted in a significant reduction in amphetamine-mediated behavior in both control and coloboma mice (##p < 0.01). Two-factor ANOVA with repeated measures for treatment with SCH23390 alone revealed significant main effects of genotype (F1,12 = 10.09, p < 0.01) and dose (F2,24 = 4.45, p < 0.05). Compared to vehicle treatment (paired Student’s t tests), 0.2 mg/kg SCH23390 significantly reduced locomotor activity in control and coloboma mice (**p < 0.01; ***p < 0.001); 0.05 mg/kg SCH23390 significantly reduced the locomotor activity of coloboma mice (*p < 0.05). Data represent total beam breaks in 1 hr after drug administration and are expressed as mean ± SEM (n=7/genotype/dose).